The acute and short-time effect of supplementation with the combination of n-3 fatty acids and acetylsalicylic acid on platelet function and plasma lipids.
Antiplatelet therapy with acetylsalicylic acid (ASA) is commonly used to reduce the risk of cardio- and cerebrovascular events. Fish consumption has been inversely related to coronary disease, which has been partly attributed to an inhibitory effect of n-3 polyunsaturated fatty acids (n-3 PUFA) on platelet production of tromboxane A2. In this study, we investigated the acute and short-time effect of supplementation with n-3 PUFA and intravenous ASA on platelet function, platelet fatty acid composition and plasma lipids. Eighteen healthy men were randomly allocated to a daily intake of 10 g n-3 PUFA or placebo. After this supplement (14 h and 14 days), blood was sampled before and after intravenous injection of 100 mg ASA. n-3 PUFA given for 14 days caused a minor inhibition of platelet reactivity but negligible compared to 100 mg ASA. No additive effect of n-3 PUFA and ASA could be demonstrated.
Svaneborg
Niels
N
Department of Clinical Chemistry, Aalborg Hospital, Denmark.
Kristensen
Steen D
SD
Hansen
Lene M
LM
Büllow
Inge
I
Husted
Steen E
SE
Schmidt
Erik B
EB
D000284:Administration, Oral; D000328:Adult; D001241:Aspirin / Q000008:administration & dosage*; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology*; D004311:Double-Blind Method; D004347:Drug Interactions; D005227:Fatty Acids / Q000097:blood; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D013997:Time Factors
D005227:Fatty Acids; D015525:Fatty Acids, Omega-3; D008055:Lipids; D008074:Lipoproteins; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin